← Back to Search

Monoclonal Antibodies

Elranatamab + Dexamethasone for Multiple Myeloma(MagnetisMM-9 Trial)

Tulane Cancer Center, New Orleans, LA
Elranatamab +1 morePhase 2Waitlist AvailableResearch Sponsored by Pfizer

MagnetisMM-9 Trial Summary

This trial is testing the safety of a new dosing method for a medication used to treat myeloma. The study will also look at how effective the medication is at different doses and how often it should be given.

Eligible Conditions
  • Multiple Myeloma

MagnetisMM-9 Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have been diagnosed with multiple myeloma according to specific criteria.
You have a condition that can be measured to track changes during the study.
You have a high level of M-protein in your blood.
You have more than 200 milligrams of M-protein in your urine over a 24-hour period.
Your blood test shows high levels of a specific type of protein and an abnormal ratio of different types of proteins.
You have not responded to at least one specific type of medication called an IMiD.
You have not responded to at least one specific type of medication.
You have not responded to at least one anti-CD38 antibody treatment.
You have not responded well to the last treatment for myeloma, or the myeloma has come back after treatment.
You are able to perform everyday activities without any major limitations.
Any side effects from previous treatment have either gone away or are very mild.

MagnetisMM-9 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with overall response rate (ORR) per International Myeloma Working Group (IMWG) criteria (Part 3).
Proportion of participants with Grade 2 or higher Cytokine Release Syndrome (CRS) (Part 1 and 2)
Secondary outcome measures
Complete Response Rate
Duration of complete response rate
Duration of response
+11 more

Side effects data

From 2013 Phase 4 trial • 122 Patients • NCT01474915
Cerebrospinal fluid leak
Deep Vein Thrombosis
Study treatment Arm

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

MagnetisMM-9 Trial Design

5Treatment groups
Experimental Treatment
Group I: Part 3Experimental Treatment1 Intervention
To explore the combination with dexamethasone
Group II: Part 2CExperimental Treatment1 Intervention
To explore higher dose intensity
Group III: Part 2BExperimental Treatment1 Intervention
Dose expansion
Group IV: Part 2AExperimental Treatment1 Intervention
Dose determination
Group V: Part 1Experimental Treatment1 Intervention
Evaluation of step-up priming dosing
First Studied
Drug Approval Stage
How many patients have taken this drug

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,513 Previous Clinical Trials
9,895,039 Total Patients Enrolled
31 Trials studying Multiple Myeloma
9,342 Patients Enrolled for Multiple Myeloma
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,435 Previous Clinical Trials
7,123,995 Total Patients Enrolled
23 Trials studying Multiple Myeloma
4,742 Patients Enrolled for Multiple Myeloma

Media Library

Elranatamab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05014412 — Phase 2
Multiple Myeloma Research Study Groups: Part 2C, Part 1, Part 2A, Part 2B, Part 3
Multiple Myeloma Clinical Trial 2023: Elranatamab Highlights & Side Effects. Trial Name: NCT05014412 — Phase 2
Elranatamab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05014412 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In which areas can individuals access this clinical trial?

"34 medical centres are currently recruiting for this study, including Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy in Long Island City, MSK Westchester in Harrison, and MSK Basking Ridge in Basking Ridge. Multiple other locations also have enrolment spots available."

Answered by AI

How many individuals are participating in this medical research?

"Affirmative. Details on clinicaltrials.gov support that this medical trial is open for recruitment, with the original posting date of October 7th 2021 and most recent update dated November 21st 2022. 76 participants from 34 different sites are needed to complete this experiment."

Answered by AI

To what extent could Elranatamab be hazardous to human health?

"After thorough evaluation, we have determined that Elranatamab is a safe enough medication to receive an assessment of 2. This rating accounts for Phase 2 trial results which demonstrate safety but lack evidence in support of efficacy."

Answered by AI

Are there any opportunities for individuals to participate in this experiment?

"Affirmative. According to details on clinicaltrials.gov, this trial is actively seeking applicants; it was first listed on October 7th 2021 and has recently been updated as of November 21st 2022. The study is currently enrolling 76 people at 34 centers around the country."

Answered by AI
~28 spots leftby Dec 2024